Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant Apr 30, 2021 Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant
Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau About New DMT Stroke Program Apr 13, 2021 Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau About New DMT Stroke Program
Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau Mar 19, 2021 Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau
DMT Update and Recap Interview with CEO Christopher Moreau and Host Cyndi Edwards of PRmediaNow Mar 18, 2021 DMT Update and Recap Interview with CEO Christopher Moreau and Host Cyndi Edwards of PRmediaNow
Could the “Spirit Molecule” DMT Assist in Stroke Recovery? – Technology Network Mar 11, 2021 Could the “Spirit Molecule” DMT Assist in Stroke Recovery? – Technology Network
Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss the DMT Stroke Program on BioPub Webcast Hosted by Dr. KSS MD, PhD Mar 4, 2021 Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss the DMT Stroke Program on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon Pharmaceuticals Looks to Highly Regarded UK Company to Conduct Phase 1 DMT Stroke Study Mar 2, 2021 Algernon Pharmaceuticals Looks to Highly Regarded UK Company to Conduct Phase 1 DMT Stroke Study
Microdose PsyCap Conference: Investment Opportunities and New Companies in the Sector Feb 28, 2021 Microdose PsyCap Conference: Investment Opportunities and New Companies in the Sector
Psychedelic Capital Virtual Investment Conference – Feb 2021 | Microdose Feb 28, 2021 Psychedelic Capital Virtual Investment Conference – Feb 2021 | Microdose
BNN Bloomberg – How Algernon Pharmaceuticals is aiming to use psychedelics to aid stroke recovery Feb 18, 2021 BNN Bloomberg – How Algernon Pharmaceuticals is aiming to use psychedelics to aid stroke recovery
Proactive – Algernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil study Feb 11, 2021 Proactive – Algernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil study
IFL Science – Psychedelic Drug DMT To Be Trialed On Stroke Victims Feb 10, 2021 IFL Science – Psychedelic Drug DMT To Be Trialed On Stroke Victims
Stroke victims to get hallucinogenic drug DMT to stave off worst effects of life-threatening condition in first-of-its-kind trial, scientists say Feb 9, 2021 Stroke victims to get hallucinogenic drug DMT to stave off worst effects of life-threatening condition in first-of-its-kind trial, scientists say
Metro UK – Stroke victims to be given psychedelic drug DMT in groundbreaking study Feb 4, 2021 Metro UK – Stroke victims to be given psychedelic drug DMT in groundbreaking study
Algernon Pharmaceuticals Launches Research Program for Treatment of Stroke Using Psychedelic Drug DMT Feb 4, 2021 Algernon Pharmaceuticals Launches Research Program for Treatment of Stroke Using Psychedelic Drug DMT
DMT Stroke Research: Algernon Pharmaceuticals Moving to the Head of the Pack Feb 4, 2021 DMT Stroke Research: Algernon Pharmaceuticals Moving to the Head of the Pack
Algernon Pharmaceuticals Targets Psychedelic Drug DMT for Stroke Program Feb 4, 2021 Algernon Pharmaceuticals Targets Psychedelic Drug DMT for Stroke Program
StreetSmart Live! Interview with CEO, Christopher Moreau and CSO, Dr. Mark Williams Dec 21, 2020 StreetSmart Live! Interview with CEO, Christopher Moreau and CSO, Dr. Mark Williams
A Letter From Algernon Pharmaceuticals CEO Christopher Moreau Dec 8, 2020 A Letter From Algernon Pharmaceuticals CEO Christopher Moreau
Algernon Pharmaceuticals CEO Christopher Moreau to present at Proactive’s One2One Virtual Investor Conference to be held December 8, 2020 Dec 3, 2020 Algernon Pharmaceuticals CEO Christopher Moreau to present at Proactive’s One2One Virtual Investor Conference to be held December 8, 2020
Algernon Pharmaceuticals Begins Screening Patients for Phase 2 Chronic Cough and IPF Study Jul 10, 2020 Algernon Pharmaceuticals Begins Screening Patients for Phase 2 Chronic Cough and IPF Study
FierceBiotech: Algernon signs Novotech up for midstage respiratory therapy test Feb 11, 2020 FierceBiotech: Algernon signs Novotech up for midstage respiratory therapy test
Pulmonary Fibrosis News: Repurposed Anti-fibrotic Medication, NP-120, Set for Phase 2 Testing for IPF Aug 6, 2019 Pulmonary Fibrosis News: Repurposed Anti-fibrotic Medication, NP-120, Set for Phase 2 Testing for IPF
